CSF markers related to pathogenetic mechanisms in Alzheimer's disease

被引：0

作者：

C. Mulder

S. N. M. Schoonenboom

L.-O. Wahlund

Ph. Scheltens

G. J. van Kamp

R. Veerhuis

C. E. Hack

M. Blomberg

R. B. H. Schutgens

P. Eikelenboom

机构：

[1] Departments of Clinical Chemistry,

[2] ,undefined

[3] Neurology,undefined

[4] ,undefined

[5] Pathology,undefined

[6] and,undefined

[7] Psychiatry,undefined

[8] Research Institute Neurosciences,undefined

[9] VU University Medical Center,undefined

[10] Amsterdam,undefined

[11] The Netherlands,undefined

[12] Department of Clinical Neuroscience,undefined

[13] Section of Geriatric Medicine,undefined

[14] Huddinge University Hospital,undefined

[15] Karolinska Institute,undefined

[16] Huddinge,undefined

[17] Sweden,undefined

来源：

Journal of Neural Transmission | 2002年 / 109卷

关键词：

Keywords: C1q; SAP; A-beta (1; 42); tau; pathogenic mechanism.;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Serum amyloid P component (SAP) and complement C1q are found highly co-localized with extracellular fibrillar amyloidβ (Aβ) deposits in Alzheimer's disease (AD) brain. Conflicting data were reported earlier about the cerebrospinal fluid (CSF) levels of SAP and C1q in AD compared to controls. The objective of the present study was to compare the levels of Aβ1–42, tau, C1q and SAP in CSF of a well characterized group of AD patients and controls, and to assess the association with dementia severity.

引用

页码：1491 / 1498

页数：7

共 50 条

[21] The etiological and pathogenetic heterogeneity of Alzheimer's disease
Frölich, L
Hoyer, S
NERVENARZT, 2002, 73 (05): : 422 - 427
[22] Molecular mechanisms and pathology of Alzheimer's disease as reflected by biological markers
Zetterberg, H.
EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 16 - 16
[23] Editorial: Mechanisms, markers and therapeutics of synaptic pathology in Alzheimer's disease
Metaxas, Athanasios
Finsen, Bente
FRONTIERS IN NEUROSCIENCE, 2022, 16
[24] CSF biomarkers in Alzheimer's disease
Peskind, ER
NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S8 - S8
[25] Cell therapy with NGF in patients with Alzheimer's disease: changes in CSF cholinergic markers
Karami, A.
Eyjolfsdottir, H.
Vijayaraghavan, S.
Kadir, A.
Linderoth, B.
Lind, G.
Andreasen, N.
Wall, A.
Seiger, A.
Almqvist, P.
Wahlberg, L.
Nordberg, A.
Darreh-Shori, T.
Eriksdotter, M.
EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 91 - 91
[26] Anxiety and depression in Alzheimer's disease: a systematic review of pathogenetic mechanisms and relation to cognitive decline
Botto, Rossana
Callai, Nicoletta
Cermelli, Aurora
Causarano, Lorenzo
Rainero, Innocenzo
NEUROLOGICAL SCIENCES, 2022, 43 (07) : 4107 - 4124
[27] Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias
Blasko, I
Lederer, W
Oberbauer, H
Walch, T
Kemmler, G
Hinterhuber, H
Marksteiner, J
Humpel, C
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2006, 21 (01) : 9 - 15
[28] Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer’s disease
Neus Barranco
Virginia Plá
Daniel Alcolea
Irene Sánchez-Domínguez
Reiner Fischer-Colbrie
Isidro Ferrer
Alberto Lleó
Fernando Aguado
Translational Neurodegeneration, 10
[29] Alzheimer's CSF markers in older schizophrenia patients
Frisoni, Giovanni B.
Prestia, Annapaola
Geroldi, Cristina
Adorni, Andrea
Ghidoni, Roberta
Amicucci, Giovanni
Bonetti, Matteo
Soricelli, Andrea
Rasser, Paul E.
Thompson, Paul M.
Giannakopoulos, Panteleimon
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2011, 26 (06) : 640 - 648
[30] Correlations between kynurenines in plasma and CSF, and their relation to markers of Alzheimer's disease pathology
Bakker, Lieke
Kohler, Sebastian
Eussen, Simone J. P. M.
Choe, Kyonghwan
van den Hove, Daniel L. A.
Kenis, Gunter
Rutten, Bart P. F.
Ulvik, Arve
Ueland, Per M.
Verhey, Frans R. J.
Ramakers, Inez H. G. B.
BRAIN BEHAVIOR AND IMMUNITY, 2023, 111 : 312 - 319

← 1 2 3 4 5 →